Literature DB >> 28582866

Neurodegenerative Markers are Increased in Postmortem BA21 Tissue from African Americans with Alzheimer's Disease.

Sherry A Ferguson1, John J Panos1, Daniel Sloper2, Vijayalakshmi Varma2.   

Abstract

BACKGROUND: Alzheimer's disease (AD) presents with an earlier onset age and increased symptom severity in African Americans and Hispanics.
OBJECTIVE: Although the prevalence of plaques and tangles may not exhibit ethnicity-related differences, levels of neurodegenerative proteins have not been described.
METHODS: Here, levels of five proteins (i.e., S100B, sRAGE, GDNF, Aβ40, and Aβ42) and the Aβ42/Aβ40 ratio were measured in postmortem samples of the middle temporal gyrus (BA21) from age-matched African Americans and Caucasians with AD (n = 6/gender/ethnicity).
RESULTS: S100B levels were increased 17% in African Americans (p < 0.003) while sRAGE was mildly decreased (p < 0.09). Aβ42 levels were increased 121% in African Americans (p < 0.02), leading to a 493% increase in the Aβ42/Aβ40 ratio (p < 0.002). Analysis of GDNF levels did not indicate any significant effects. There were no significant effects of gender and no significant ethnicity with gender interactions on any analyte. Effect size calculations indicated "medium" to "very large" effects.
CONCLUSION: S100B is typically elevated in AD cases; however, the increased levels in African Americans here may be indicative of increased severity in specific populations. Increased Aβ42/Aβ40 ratios in the current study are compatible with increased disease severity and might indicate increased AD pathogenesis in African Americans. Overall, these results are compatible with a hypothesis of increased neuroinflammation in African Americans with AD.

Entities:  

Keywords:  African American; Caucasian; S100B; amyloid-beta; ethnic groups; racial differences; sRAGE; temporal gyrus

Mesh:

Substances:

Year:  2017        PMID: 28582866     DOI: 10.3233/JAD-170204

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.

Authors:  Mariko Sawa; Cassia Overk; Ann Becker; Dominique Derse; Ricardo Albay; Kim Weldy; Ahmad Salehi; Thomas G Beach; Eric Doran; Elizabeth Head; Y Eugene Yu; William C Mobley
Journal:  Alzheimers Dement       Date:  2021-11-10       Impact factor: 16.655

2.  Increased inflammation in BA21 brain tissue from African Americans with Alzheimer's disease.

Authors:  Sherry A Ferguson; Vijayalakshmi Varma; Daniel Sloper; John J Panos; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2019-12-10       Impact factor: 3.584

Review 3.  The Potential of 'Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer's Disease in African Americans.

Authors:  Kaitlyn E Stepler; Renã A S Robinson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Exposing the Brain Proteomic Signatures of Alzheimer's Disease in Diverse Racial Groups: Leveraging Multiple Data Sets and Machine Learning.

Authors:  Heather Desaire; Kaitlyn E Stepler; Renã A S Robinson
Journal:  J Proteome Res       Date:  2022-03-11       Impact factor: 5.370

5.  MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update.

Authors:  Subodh Kumar; P Hemachandra Reddy
Journal:  Front Aging Neurosci       Date:  2018-02-23       Impact factor: 5.750

Review 6.  Culture, Ethnicity, and Level of Education in Alzheimer's Disease.

Authors:  Mónica Rosselli; Idaly Vélez Uribe; Emily Ahne; Layaly Shihadeh
Journal:  Neurotherapeutics       Date:  2022-03-28       Impact factor: 7.620

7.  Increased Serum NSE and S100B Indicate Neuronal and Glial Alterations in Subjects Under 71 Years With Mild Neurocognitive Disorder/Mild Cognitive Impairment.

Authors:  Maryna Polyakova; Karsten Mueller; Katrin Arelin; Leonie Lampe; Francisca S Rodriguez; Tobias Luck; Jürgen Kratzsch; Karl-Titus Hoffmann; Steffi Riedel-Heller; Arno Villringer; Peter Schoenknecht; Matthias L Schroeter
Journal:  Front Cell Neurosci       Date:  2022-07-14       Impact factor: 6.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.